Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea FDA Sends Precautionary Notice To Doctors For Diabetes Drugs Containing Rosiglitazone

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's Food and Drug Administration issued its second precautionary notice to doctors, calling for caution in prescribing diabetes drugs containing rosiglitazone, including GlaxoSmithKline's Avandia and Avandaryl, Sanofi Aventis' Amavan, and local Korean Yuhan Corp.'s generic rosiglitazone

You may also be interested in...



Like U.S. Counterparts, South Korea FDA Regulators Move To Severely Restrict Use Of Diabetes Treatments Including GSK's Avandia

SEOUL - Following a U.S. FDA action to drastically limit the use of diabetes treatments containing rosiglitazone, Korea FDA is adopting similar measures, advising doctors and patients not to use 15 of these medicines available locally including GlaxoSmithKline's Avandia

Like U.S. Counterparts, South Korea FDA Regulators Move To Severely Restrict Use Of Diabetes Treatments Including GSK's Avandia

SEOUL - Following a U.S. FDA action to drastically limit the use of diabetes treatments containing rosiglitazone, Korea FDA is adopting similar measures, advising doctors and patients not to use 15 of these medicines available locally including GlaxoSmithKline's Avandia

Saudi Regulators Suspend Use Of Avandia; GSK Says Action Not Based On Recent Data

In a new development following recent attention brought by a U.S. Senate Finance Committee report, the Saudi Arabia Food and Drug Authority has suspended the use of GlaxoSmithKline's Avandia (rosiglitazone) for six months while a review is under way

Related Content

UsernamePublicRestriction

Register

SC074487

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel